Component
New vertebral fracture incidence
New vertebral fracture incidence. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Adding menatetrenone to calcium did not significantly reduce new vertebral fractures in the full analysis set; the clinical-fracture secondary difference was also nonsignificant.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/k2-research/19082528.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "6d29b8f43348d8acd6ee85d4f65bb0cdd1352dd6f5113f58d7e58d7196bd96f5", "start_char": 0, "end_char": 1657, "text_sha256": "6d29b8f43348d8acd6ee85d4f65bb0cdd1352dd6f5113f58d7e58d7196bd96f5"}
- experimental_model
- Randomized open-label trial with blinded endpoint evaluation
- exposure
- Calcium alone versus calcium plus menatetrenone; 36-month primary and 48-month secondary endpoints
- limitations
- Full-analysis null result; advanced-osteoporosis subgroup signals are exploratory and do not replace the overall endpoint.
- nutrient_topic
- Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. · Vitamin K2 / menaquinone family
- organism
- 4378 osteoporotic postmenopausal women
- plain_language
- A large trial did not establish a general fracture-prevention benefit from adding MK-4.
- primary_references
- [k2-p19082528] Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. (2009). https://pubmed.ncbi.nlm.nih.gov/19082528/ DOI: 10.1007/s00774-008-0008-8
- tissue_or_cell_type
- Vertebral and clinical fractures
Vitamin K2: menaquinone forms, carboxylation, recycling and nutrient interactions (2026-09-17) · lines 1111–1122
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized open-label trial with blinded endpoint evaluation · source_derived_draft · unverified_draft
### k2-mk4-fractures-null Adding menatetrenone to calcium did not significantly reduce new vertebral fractures in the full analysis set; the clinical-fracture secondary difference was also nonsignificant. Condition category: normal nutrient_topic: Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. plain_language: A large trial did not establish a general fracture-prevention benefit from adding MK-4. organism: 4378 osteoporotic postmenopausal women tissue_or_cell_type: Vertebral and clinical fractures experimental_model: Randomized open-label trial with blinded endpoint evaluation limitations: Full-analysis null result; advanced-osteoporosis subgroup signals are exploratory and do not replace the overall endpoint. exposure: Calcium alone versus calcium plus menatetrenone; 36-month primary and 48-month secondary endpoints evidence_span: {"source_cache": "artifacts/k2-research/19082528.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "6d29b8f43348d8acd6ee85d4f65bb0cdd1352dd6f5113f58d7e58d7196bd96f5", "start_char": 0, "end_char": 1657, "text_sha256": "6d29b8f43348d8acd6ee85d4f65bb0cdd1352dd6f5113f58d7e58d7196bd96f5"} [k2-p19082528] Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. (2009). https://pubmed.ncbi.nlm.nih.gov/19082528/ DOI: 10.1007/s00774-008-0008-8
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.